Developer docs
API playgroundTry for free, no card

Search company profiles

RareCyte

Full company profile

uuid0000fzi

Namestring
RareCyte
Legal namestring
RareCyte, Inc.
Websiteurl
rarecyte.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

RareCyte is a Seattle-based private life sciences tools company that develops and commercializes precision biology platforms spanning two complementary technology pillars: the Orion spatial proteomics platform, which performs 20-channel single-round multiplex immunofluorescence imaging on tissue samples, and the CyteFinder liquid biopsy platform, which uses automated fluorescent imaging with machine-learning-assisted scoring to detect and phenotype circulating tumor cells (CTCs) at single-cell sensitivity. The Orion platform is offered in two commercial configurations — the Orion HT, a 30-slide clinical-scale instrument designed for unattended 24/7 operation, and the Orion LE, an entry-level instrument for translational and panel-development work — and is supported by a catalog of more than 500 validated antibody conjugates spanning 200+ biomarkers, with planned expansion to 300+ by end of 2026. The CyteFinder platform is paired with the AccuCyte sample preparation system, which transfers nucleated cells from blood to slides with minimal cell loss and supports seven-day blood stability for global clinical trial logistics, and with RarePlex CTC assay kits (including AR/ARv7, HER2/ER, and PD-L1 panels) plus a Developer kit for custom biomarker addition. A more recent addition is the TrophoSeq assay for non-invasive isolation and sequencing of circulating trophoblasts from maternal blood, used in fetal growth restriction research.

RareCyte monetizes through a hybrid revenue model combining capital instrument sales (Orion HT, Orion LE, CyteFinder II, CyteFinder II HT), recurring consumables and reagent sales (RarePlex kits, Orion validated antibodies), subscription-style data management and analysis software (OMERO Plus integration, OrionQuantification), and Precision Biology Services — a CLIA-accredited, ISO 13485:2016-certified laboratory offering custom assay development, clinical trial testing, and biomarker research delivered from Seattle. Pricing is quote-based; published reference points include roughly $25-$30 per biomarker per slide for Orion reagents, with a 15-plex panel typically under $500 per slide. Customers span large biopharma (Eli Lilly, Agenus, Astellas, KSQ Therapeutics), elite academic medical centers (Harvard Medical School, Weill Cornell, Mass General, University of Washington, University of Sydney), and Contract Research Organizations (Navigate BioPharma, CellCarta, NeoGenomics, ICON plc), with the company stating it has supported 60+ clinical trials and developed 100+ custom assays across diverse indications.

The company sells directly in North America and through a network of regional distributors covering Western and Eastern Europe, the Middle East, and Asia-Pacific (Japan, Korea, Singapore, Thailand). Leadership includes Joe Victor as President and CEO, Neil Kennedy as President (appointed April 2026 to lead commercial scaling), Stephen D. Reichenbach as CFO, and founder Ron Seubert, with Eric Kaldjian (SVP Clinical Research, previously CMO) and Tad George (SVP Biology R&D) overseeing clinical and R&D functions. Founded in 2006, RareCyte has raised approximately $74 million in disclosed equity financing across rounds in 2017, 2019, 2021, and 2024, plus a 2025 Gates Foundation grant.

Short descriptiontext

RareCyte is a Seattle-based life sciences tools company that develops spatial proteomics (Orion, 20-channel multiplex imaging) and liquid biopsy (CyteFinder CTC) platforms, serving biopharma, academic medical centers, and CROs with instruments, reagents, and CLIA-accredited laboratory services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial biology instruments, liquid biopsy platforms, spatial proteomics, circulating tumor cells, biomarker development
Industry1 code
PRIMARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code2 codes
  • Medical Laboratories621511
  • Medical Equipment and Supplies Manufacturing3391
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Life Sciences Research Instruments
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Spatial Biology Instruments
TypeHardware Sales
Description

Sale of Orion and CyteFinder imaging instruments to biopharma, academic, and clinical research laboratories.

rarecyte.com
2Reagents and Consumables
TypeHardware Sales
Description

Sale of antibody conjugates, RarePlex CTC assay kits, and consumables for use with Orion and CyteFinder platforms. Over 500 products and 200+ biomarkers available.

rarecyte.com
3Precision Biology Services
TypeProfessional Services
Description

CLIA-accredited laboratory services including custom assay development, clinical trial testing, and biomarker research. Services performed under CLIA and ISO 13485 certifications.

rarecyte.com
4Software Applications
TypeSubscription Recurring
Description

Software products including OrionQuantification, OMERO Plus data management, and analysis tools for spatial biology data.

rarecyte.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels10 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Enterprise instrument systems
ModelOtherBilling cadenceMulti-year contract
Notes

Orion HT, Orion LE, CyteFinder II, and CyteFinder II HT instruments available through direct sales. No public pricing disclosed.

rarecyte.com
2Per-slide reagent costs
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Average cost of approximately $25-30 per biomarker per slide. A 15-plex panel typically costs less than $500 per slide.

rarecyte.com
3Laboratory services
ModelOtherBilling cadenceMulti-year contract
Notes

Custom assay development, clinical trial testing, and biomarker research services. Pricing determined per project through consultation.

rarecyte.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Orion™
Description

High-plex spatial proteomics platform for clinical-scale biomarker development, featuring 20-channel single-round imaging technology.

rarecyte.com
+5 more records
Core offering1 text field

RareCyte develops and sells the Orion spatial proteomics platform and the CyteFinder liquid biopsy platform, along with associated reagents, consumables, and CLIA-accredited Precision Biology laboratory services. The company's offerings enable biopharma, academic medical research, and contract research customers to perform 20-channel single-round multiplex tissue imaging and ultra-sensitive circulating tumor cell analysis for biomarker development and clinical trial testing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 96% CTC recovery rate in validation studies
+3 more records
Product overview1 text field

RareCyte offers two integrated technology platforms — the Orion™ Spatial Proteomics platform and the CyteFinder® Rare Cell Detection platform — supported by a portfolio of consumable reagents and Precision Biology™ laboratory services. The Orion platform (including Orion HT and Orion LE instruments) provides high-plex spatial proteomics imaging with 20 channels in a single round, driven by validated reagent products (500+ antibody conjugates across 200+ biomarkers) and data analysis tools including OMERO Plus integration and Halo AI image analysis. The CyteFinder platform (CyteFinder II and CyteFinder II HT instruments) paired with AccuCyte® sample preparation and RarePlex® CTC assay kits (AR/ARv7, HER2/ER, PD-L1, and Developer kits) enables liquid biopsy workflows for circulating tumor cell detection. Both platforms feed into Precision Biology Services — a CLIA- and ISO 13485-certified laboratory service offering custom assay development, clinical trial testing, and biomarker research delivered from Seattle-based facilities. Recent additions include the TrophoSeq™ circulating trophoblast assay for maternal-fetal health research.

Product and service15 records
1Orion Spatial Proteomics Platform
CategorySpatial proteomics platform
Description

High-plex spatial proteomics platform delivering 20-channel multiplex immunofluorescence imaging of tissue samples in a single round for biomarker development and clinical research.

2Orion HT
CategorySpatial proteomics instrument
Description

High-capacity, clinical-scale spatial proteomics instrument with 30-slide automation, 24/7 unattended operation, 20-channel single-round whole-slide scanning, sub-micron resolution, and barcode-driven sample chain-of-custody. Designed for large cohort biomarker programs and multi-user environments.

3Orion LE
CategorySpatial proteomics instrument
Description

Affordable and streamlined spatial proteomics instrument for biomarker panel development, assay optimization, and translational studies, complementing the high-throughput Orion HT system.

4CyteFinder Rare Cell Detection Platform
CategoryLiquid biopsy platform
Description

Automated fluorescent imaging platform with integrated machine learning for high-sensitivity detection and phenotyping of circulating tumor cells (CTCs) and other rare cells from liquid biopsy samples.

5CyteFinder II
CategoryLiquid biopsy instrument
Description

CyteFinder instrument with CytePicker retrieval module for single-cell or tissue micro-region isolation and molecular analysis, 6-channel immunofluorescence and brightfield imaging, sub-cellular resolution.

6CyteFinder II HT
CategoryLiquid biopsy instrument
Description

High-capacity CyteFinder instrument with 80-slide capacity for 24/7 unattended scanning, barcode workflow, immunofluorescence and brightfield imaging modes, 6 channels, and ML-based CTC scoring.

7AccuCyte Sample Preparation System
CategorySample preparation instrument
Description

Sample preparation system that transfers nucleated cells from blood to slides with virtually no cell loss, enabling 7-day blood stability for global shipment and 3-year slide stability for sample banking and batch testing.

8RarePlex CTC Assays
CategoryCTC assay kit
Description

Comprehensive suite of circulating tumor cell (CTC) detection and phenotyping assays for liquid biopsy, covering prostate, breast, lung, melanoma, and immuno-oncology applications with up to 5-plex customizable panels.

9RarePlex AR/ARv7 CTC Panel Kit
CategoryCTC assay kit
Description

Panel kit for prostate cancer CTC analysis detecting androgen receptor (AR) and androgen receptor splice variant 7 (ARv7) biomarker expression on CTCs, suitable for multi-center clinical trials.

10RarePlex HER2/ER CTC Panel Kit
CategoryCTC assay kit
Description

Panel kit for breast cancer CTC analysis detecting HER2 and ER biomarker expression on CTCs, suitable for large multi-center clinical trials.

11RarePlex PD-L1 CTC Panel Kit
CategoryCTC assay kit
Description

Panel kit for immuno-oncology applications detecting PD-L1 expression on CTCs for measuring biomarker response to immune checkpoint inhibitor therapies in clinical trials.

12RarePlex Developer Kit
CategoryCTC assay kit
Description

Developer technology enabling users to add up to two custom biomarkers to RarePlex CTC assays, using 405 or 488 channel chemistry, for maximum flexibility in custom assay development.

13TrophoSeq Assay
CategoryLiquid biopsy assay
Description

Liquid biopsy assay for non-invasive isolation and sequencing of circulating trophoblasts (circTBs) from maternal blood, providing a molecular window into placental physiology for fetal growth restriction research.

14Precision Biology Services
CategoryLaboratory services
Description

End-to-end laboratory services including custom assay development, clinical trial testing, and biomarker research powered by Orion and CyteFinder platforms, delivered from CLIA-accredited and ISO 13485-certified Seattle-based labs.

15Orion Validated Reagents and Panels
CategoryReagent/antibody conjugate
Description

Portfolio of over 500 validated antibody conjugates spanning 200+ biomarkers for the Orion platform, all validated for single-round multiplex compatibility with a single antigen retrieval condition, enabling rapid custom panel assembly.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-21
Description

Partnership with Prof. Mushi Matjila and Dr. Nadia Ikumi at UCT to conduct fetal growth restriction research. Study will enroll pregnant women at Groote Schuur Hospital in South Africa, generating cellular and transcriptomic profiles of circulating trophoblasts.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-09
Description

Collaboration to provide enhanced spatial biology capabilities using the Orion platform. Navigate offers multiplex spatial biology assay services for rapid, whole-slide imaging and analysis at subcellular resolution, featuring ready-to-run assay panels and customization for studies across multiple drug targets and therapeutic areas.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-09
Description

Qualified Service Provider offering validated Orion and CyteFinder workflows, trained and certified directly by RareCyte.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-09
Description

Qualified Service Provider offering validated Orion and CyteFinder workflows, trained and certified directly by RareCyte.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-09
Description

Qualified Service Provider offering validated Orion and CyteFinder workflows, trained and certified directly by RareCyte.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-22
Description

Botensilimab/Balstilimab breakthrough data presented at ASCO-GI using Orion spatial biomarker analysis, demonstrating significant tumor-shrinking activity in MSS colorectal cancer.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-06-29
Description

Astellas established TME iLab open innovation hub using Orion spatial biology platform in Mitsui Fudosan's research facility in Japan for tumor microenvironment research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-14
Description

Selected for the $50M In Utero program to create scalable capacity to measure, model and predict gestational development. RareCyte utilizes its rare cell platform for non-invasive characterization of the placenta using AccuCyte/CyteFinder technology to isolate circulating trophoblasts.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-03
Description

Funded for CA CURE initiative to test gastrointestinal cancer patient samples within clinical trials to determine CTC burden and selected biomarker analysis.

10Harvard Medical School
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Professor Peter K. Sorger and Dr. Sandro Santagata's team published Nature Cancer study identifying spatial signatures predictive of survival/recurrence in colorectal cancer patients using Orion platform, analyzing over 100 million cells from 74 patients.

rarecyte.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Pashtoon Kasi led study published in Nature Oncogene demonstrating neoadjuvant immunotherapy response in MSS CRC using Orion spatial biology platform.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

10x Genomics' Visium HD and Xenium in situ platforms are direct competitors to RareCyte's Orion spatial biology platform, serving the same biopharma and academic translational research customers with multiplex spatial omics offerings.

TypeDirect peer
Description

NanoString's GeoMx DSP and CosMx SMI spatial biology platforms directly compete with RareCyte's Orion — both offering high-plex spatial proteomics/transcriptomics for biopharma biomarker programs and clinical research.

TypeDirect peer
Description

Akoya's PhenoCycler-Fusion (formerly CODEX) and PhenoImager HT spatial proteomics platforms directly compete with RareCyte's Orion, targeting immuno-oncology and tumor microenvironment research at biopharma and academic customers.

TypeDirect peer
Description

Menarini's CELLSEARCH is the established circulating tumor cell (CTC) platform and a direct competitor to RareCyte's CyteFinder in clinical trial CTC enumeration and monitoring for oncology drug development.

TypeEmerging player
Description

Stellaromics is a recent spatial biology entrant that, like RareCyte, has been highlighted as a driver of innovation and funding momentum in the high-plex spatial omics market — an emerging peer for spatial biology programs.

TypeEmerging player
Description

Curio offers spatial transcriptomics via its Curio Seeker platform for tissue profiling. RareCyte's newly appointed President (Neil Kennedy) was previously CCO of Curio before its acquisition by Takara Bio, indicating operational overlap and competitor reference.

TypeBroad incumbent
Description

Standard BioTools' Hyperion Imaging Mass Cytometry (tissue and Imaging Mass Cytometry) provides an alternative high-plex spatial biology approach serving translational research customers similar to RareCyte's Orion platform.

TypeBroad incumbent
Description

Bruker acquired NanoString in 2024 and now bundles spatial biology with broader mass spectrometry and proteomics instrumentation. As a larger incumbent, Bruker can bundle spatial workflow solutions that compete with RareCyte's Orion + services offering.

TypeOthers
Description

NeoGenomics is both a partner (certified CRO service provider for Orion/CyteFinder workflows) and adjacent competitor — its own oncology-focused clinical lab services and spatial biology capabilities place it as ecosystem-relevant compared with RareCyte's Precision Biology Services.

TypeBroad incumbent
Description

Bio-Techne's spatial biology reagents (RNAscope in situ hybridization, Eclipse antibody conjugates) and broader proteomics catalog serve overlapping translational research customers, with reagent bundling strategies that can compete with RareCyte's 500+ reagent/200+ biomarker offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RareCyte

Life Sciences Research Instrumentsrarecyte.com

RareCyte is a Seattle-based life sciences tools company that develops spatial proteomics (Orion, 20-channel multiplex imaging) and liquid biopsy (CyteFinder CTC) platforms, serving biopharma, academic medical centers, and CROs with instruments, reagents, and CLIA-accredited laboratory services.

What RareCyte does

RareCyte is a Seattle-based private life sciences tools company that develops and commercializes precision biology platforms spanning two complementary technology pillars: the Orion spatial proteomics platform, which performs 20-channel single-round multiplex immunofluorescence imaging on tissue samples, and the CyteFinder liquid biopsy platform, which uses automated fluorescent imaging with machine-learning-assisted scoring to detect and phenotype circulating tumor cells (CTCs) at single-cell sensitivity. The Orion platform is offered in two commercial configurations — the Orion HT, a 30-slide clinical-scale instrument designed for unattended 24/7 operation, and the Orion LE, an entry-level instrument for translational and panel-development work — and is supported by a catalog of more than 500 validated antibody conjugates spanning 200+ biomarkers, with planned expansion to 300+ by end of 2026. The CyteFinder platform is paired with the AccuCyte sample preparation system, which transfers nucleated cells from blood to slides with minimal cell loss and supports seven-day blood stability for global clinical trial logistics, and with RarePlex CTC assay kits (including AR/ARv7, HER2/ER, and PD-L1 panels) plus a Developer kit for custom biomarker addition. A more recent addition is the TrophoSeq assay for non-invasive isolation and sequencing of circulating trophoblasts from maternal blood, used in fetal growth restriction research.

RareCyte monetizes through a hybrid revenue model combining capital instrument sales (Orion HT, Orion LE, CyteFinder II, CyteFinder II HT), recurring consumables and reagent sales (RarePlex kits, Orion validated antibodies), subscription-style data management and analysis software (OMERO Plus integration, OrionQuantification), and Precision Biology Services — a CLIA-accredited, ISO 13485:2016-certified laboratory offering custom assay development, clinical trial testing, and biomarker research delivered from Seattle. Pricing is quote-based; published reference points include roughly $25-$30 per biomarker per slide for Orion reagents, with a 15-plex panel typically under $500 per slide. Customers span large biopharma (Eli Lilly, Agenus, Astellas, KSQ Therapeutics), elite academic medical centers (Harvard Medical School, Weill Cornell, Mass General, University of Washington, University of Sydney), and Contract Research Organizations (Navigate BioPharma, CellCarta, NeoGenomics, ICON plc), with the company stating it has supported 60+ clinical trials and developed 100+ custom assays across diverse indications.

The company sells directly in North America and through a network of regional distributors covering Western and Eastern Europe, the Middle East, and Asia-Pacific (Japan, Korea, Singapore, Thailand). Leadership includes Joe Victor as President and CEO, Neil Kennedy as President (appointed April 2026 to lead commercial scaling), Stephen D. Reichenbach as CFO, and founder Ron Seubert, with Eric Kaldjian (SVP Clinical Research, previously CMO) and Tad George (SVP Biology R&D) overseeing clinical and R&D functions. Founded in 2006, RareCyte has raised approximately $74 million in disclosed equity financing across rounds in 2017, 2019, 2021, and 2024, plus a 2025 Gates Foundation grant.

RareCyte firmographics

Firmographics
Name
RareCyte
Legal name
RareCyte, Inc.
Website
https://rarecyte.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
RareCyte is a Seattle-based life sciences tools company that develops spatial proteomics (Orion, 20-channel multiplex imaging) and liquid biopsy (CyteFinder CTC) platforms, serving biopharma, academic medical centers, and CROs with instruments, reagents, and CLIA-accredited laboratory services.
Ownership category
akta.pro rank

RareCyte industry classification

Industry
Product category
Life Sciences Research Instruments
NAICS
Medical Laboratories (621511), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Spatial biology instruments
  • Liquid biopsy platforms
  • Spatial proteomics
  • Circulating tumor cells
  • Biomarker development

Where RareCyte is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

RareCyte business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Spatial Biology Instruments: Sale of Orion and CyteFinder imaging instruments to biopharma, academic, and clinical research laboratories.
  2. Reagents and Consumables: Sale of antibody conjugates, RarePlex CTC assay kits, and consumables for use with Orion and CyteFinder platforms. Over 500 products and 200+ biomarkers available.
  3. Precision Biology Services: CLIA-accredited laboratory services including custom assay development, clinical trial testing, and biomarker research. Services performed under CLIA and ISO 13485 certifications.
  4. Software Applications: Software products including OrionQuantification, OMERO Plus data management, and analysis tools for spatial biology data.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise instrument systems
Unit PricingPay-as-you-goPer-slide reagent costs
OtherMulti-year contractLaboratory services

Go-to-market motion3 records

Distribution channels10 records

Marketing channels6 records

RareCyte product offering

Product offering

Core offering

RareCyte develops and sells the Orion spatial proteomics platform and the CyteFinder liquid biopsy platform, along with associated reagents, consumables, and CLIA-accredited Precision Biology laboratory services. The company's offerings enable biopharma, academic medical research, and contract research customers to perform 20-channel single-round multiplex tissue imaging and ultra-sensitive circulating tumor cell analysis for biomarker development and clinical trial testing.

Product overview

RareCyte offers two integrated technology platforms — the Orion™ Spatial Proteomics platform and the CyteFinder® Rare Cell Detection platform — supported by a portfolio of consumable reagents and Precision Biology™ laboratory services. The Orion platform (including Orion HT and Orion LE instruments) provides high-plex spatial proteomics imaging with 20 channels in a single round, driven by validated reagent products (500+ antibody conjugates across 200+ biomarkers) and data analysis tools including OMERO Plus integration and Halo AI image analysis. The CyteFinder platform (CyteFinder II and CyteFinder II HT instruments) paired with AccuCyte® sample preparation and RarePlex® CTC assay kits (AR/ARv7, HER2/ER, PD-L1, and Developer kits) enables liquid biopsy workflows for circulating tumor cell detection. Both platforms feed into Precision Biology Services — a CLIA- and ISO 13485-certified laboratory service offering custom assay development, clinical trial testing, and biomarker research delivered from Seattle-based facilities. Recent additions include the TrophoSeq™ circulating trophoblast assay for maternal-fetal health research.

Differentiator

Problem solved

Functional benefit

Brands

  • Orion™: High-plex spatial proteomics platform for clinical-scale biomarker development, featuring 20-channel single-round imaging technology.
  • CyteFinder®
  • AccuCyte®
  • RarePlex®
  • Precision Biology™
  • TrophoSeq™

Products and services

  • Orion Spatial Proteomics Platform High-plex spatial proteomics platform delivering 20-channel multiplex immunofluorescence imaging of tissue samples in a single round for biomarker development and clinical research.
  • Orion HT High-capacity, clinical-scale spatial proteomics instrument with 30-slide automation, 24/7 unattended operation, 20-channel single-round whole-slide scanning, sub-micron resolution, and barcode-driven sample chain-of-custody. Designed for large cohort biomarker programs and multi-user environments.
  • Orion LE Affordable and streamlined spatial proteomics instrument for biomarker panel development, assay optimization, and translational studies, complementing the high-throughput Orion HT system.
  • CyteFinder Rare Cell Detection Platform Automated fluorescent imaging platform with integrated machine learning for high-sensitivity detection and phenotyping of circulating tumor cells (CTCs) and other rare cells from liquid biopsy samples.
  • CyteFinder II CyteFinder instrument with CytePicker retrieval module for single-cell or tissue micro-region isolation and molecular analysis, 6-channel immunofluorescence and brightfield imaging, sub-cellular resolution.
  • CyteFinder II HT High-capacity CyteFinder instrument with 80-slide capacity for 24/7 unattended scanning, barcode workflow, immunofluorescence and brightfield imaging modes, 6 channels, and ML-based CTC scoring.
  • AccuCyte Sample Preparation System Sample preparation system that transfers nucleated cells from blood to slides with virtually no cell loss, enabling 7-day blood stability for global shipment and 3-year slide stability for sample banking and batch testing.
  • RarePlex CTC Assays Comprehensive suite of circulating tumor cell (CTC) detection and phenotyping assays for liquid biopsy, covering prostate, breast, lung, melanoma, and immuno-oncology applications with up to 5-plex customizable panels.
  • RarePlex AR/ARv7 CTC Panel Kit Panel kit for prostate cancer CTC analysis detecting androgen receptor (AR) and androgen receptor splice variant 7 (ARv7) biomarker expression on CTCs, suitable for multi-center clinical trials.
  • RarePlex HER2/ER CTC Panel Kit Panel kit for breast cancer CTC analysis detecting HER2 and ER biomarker expression on CTCs, suitable for large multi-center clinical trials.
  • RarePlex PD-L1 CTC Panel Kit Panel kit for immuno-oncology applications detecting PD-L1 expression on CTCs for measuring biomarker response to immune checkpoint inhibitor therapies in clinical trials.
  • RarePlex Developer Kit Developer technology enabling users to add up to two custom biomarkers to RarePlex CTC assays, using 405 or 488 channel chemistry, for maximum flexibility in custom assay development.
  • TrophoSeq Assay Liquid biopsy assay for non-invasive isolation and sequencing of circulating trophoblasts (circTBs) from maternal blood, providing a molecular window into placental physiology for fetal growth restriction research.
  • Precision Biology Services End-to-end laboratory services including custom assay development, clinical trial testing, and biomarker research powered by Orion and CyteFinder platforms, delivered from CLIA-accredited and ISO 13485-certified Seattle-based labs.
  • Orion Validated Reagents and Panels Portfolio of over 500 validated antibody conjugates spanning 200+ biomarkers for the Orion platform, all validated for single-round multiplex compatibility with a single antigen retrieval condition, enabling rapid custom panel assembly.

Quantifiable outcome

  • 96% CTC recovery rate in validation studies
  • +3 more outcomes

Companies that use RareCyte

Customer profile

Named customers11 records

Segments4 records

Ideal customer profiles4 records

RareCyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature6 records

RareCyte partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • University of Cape Town (UCT)coreStrategic or Co-development Partner · 21 August 2025Partnership with Prof. Mushi Matjila and Dr. Nadia Ikumi at UCT to conduct fetal growth restriction research. Study will enroll pregnant women at Groote Schuur Hospital in South Africa, generating cellular and transcriptomic profiles of circulating trophoblasts.
  • Navigate BioPharma Services, Inc.coreStrategic or Co-development Partner · 9 April 2024Collaboration to provide enhanced spatial biology capabilities using the Orion platform. Navigate offers multiplex spatial biology assay services for rapid, whole-slide imaging and analysis at subcellular resolution, featuring ready-to-run assay panels and customization for studies across multiple drug targets and therapeutic areas.
  • CellCartaminorChannel Partner/ Reseller/ Distributor · 9 April 2024Qualified Service Provider offering validated Orion and CyteFinder workflows, trained and certified directly by RareCyte.
  • NeoGenomicsminorChannel Partner/ Reseller/ Distributor · 9 April 2024Qualified Service Provider offering validated Orion and CyteFinder workflows, trained and certified directly by RareCyte.
  • ICON plcminorChannel Partner/ Reseller/ Distributor · 9 April 2024Qualified Service Provider offering validated Orion and CyteFinder workflows, trained and certified directly by RareCyte.
  • Agenus Inc.minorStrategic or Co-development Partner · 22 January 2024Botensilimab/Balstilimab breakthrough data presented at ASCO-GI using Orion spatial biomarker analysis, demonstrating significant tumor-shrinking activity in MSS colorectal cancer.
  • Astellas Pharma Inc.minorChannel Partner/ Reseller/ Distributor · 29 June 2023Astellas established TME iLab open innovation hub using Orion spatial biology platform in Mitsui Fudosan's research facility in Japan for tumor microenvironment research.
  • Wellcome LeapcoreStrategic or Co-development Partner · 14 November 2022Selected for the $50M In Utero program to create scalable capacity to measure, model and predict gestational development. RareCyte utilizes its rare cell platform for non-invasive characterization of the placenta using AccuCyte/CyteFinder technology to isolate circulating trophoblasts.
  • GastroIntestinal Research Foundation (GIRF)minorStrategic or Co-development Partner · 3 November 2022Funded for CA CURE initiative to test gastrointestinal cancer patient samples within clinical trials to determine CTC burden and selected biomarker analysis.
  • Harvard Medical SchoolcoreStrategic or Co-development PartnerProfessor Peter K. Sorger and Dr. Sandro Santagata's team published Nature Cancer study identifying spatial signatures predictive of survival/recurrence in colorectal cancer patients using Orion platform, analyzing over 100 million cells from 74 patients.
  • Weill Cornell MedicinecoreStrategic or Co-development PartnerDr. Pashtoon Kasi led study published in Nature Oncogene demonstrating neoadjuvant immunotherapy response in MSS CRC using Orion spatial biology platform.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

RareCyte competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: 10x Genomics' Visium HD and Xenium in situ platforms are direct competitors to RareCyte's Orion spatial biology platform, serving the same biopharma and academic translational research customers with multiplex spatial omics offerings.
  • NanoString Technologies (Bruker Spatial Biology): NanoString's GeoMx DSP and CosMx SMI spatial biology platforms directly compete with RareCyte's Orion — both offering high-plex spatial proteomics/transcriptomics for biopharma biomarker programs and clinical research.
  • Akoya Biosciences: Akoya's PhenoCycler-Fusion (formerly CODEX) and PhenoImager HT spatial proteomics platforms directly compete with RareCyte's Orion, targeting immuno-oncology and tumor microenvironment research at biopharma and academic customers.
  • Menarini Silicon Biosystems: Menarini's CELLSEARCH is the established circulating tumor cell (CTC) platform and a direct competitor to RareCyte's CyteFinder in clinical trial CTC enumeration and monitoring for oncology drug development.

Emerging players

  • Stellaromics: Stellaromics is a recent spatial biology entrant that, like RareCyte, has been highlighted as a driver of innovation and funding momentum in the high-plex spatial omics market — an emerging peer for spatial biology programs.
  • Curio Bioscience: Curio offers spatial transcriptomics via its Curio Seeker platform for tissue profiling. RareCyte's newly appointed President (Neil Kennedy) was previously CCO of Curio before its acquisition by Takara Bio, indicating operational overlap and competitor reference.

Broad incumbents

  • Standard BioTools (formerly Fluidigm): Standard BioTools' Hyperion Imaging Mass Cytometry (tissue and Imaging Mass Cytometry) provides an alternative high-plex spatial biology approach serving translational research customers similar to RareCyte's Orion platform.
  • Bruker Corporation: Bruker acquired NanoString in 2024 and now bundles spatial biology with broader mass spectrometry and proteomics instrumentation. As a larger incumbent, Bruker can bundle spatial workflow solutions that compete with RareCyte's Orion + services offering.
  • Bio-Techne: Bio-Techne's spatial biology reagents (RNAscope in situ hybridization, Eclipse antibody conjugates) and broader proteomics catalog serve overlapping translational research customers, with reagent bundling strategies that can compete with RareCyte's 500+ reagent/200+ biomarker offerings.

Others

  • NeoGenomics: NeoGenomics is both a partner (certified CRO service provider for Orion/CyteFinder workflows) and adjacent competitor — its own oncology-focused clinical lab services and spatial biology capabilities place it as ecosystem-relevant compared with RareCyte's Precision Biology Services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

RareCyte social profiles

Digital presence

RareCyte compliance and trust

Trust signal

Compliance3 records

RareCyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RareCyte leadership team

Management profile

Number of profiles

Profiles8 records

RareCyte funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RareCyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RareCyte

What does RareCyte do?

RareCyte develops and sells the Orion spatial proteomics platform and the CyteFinder liquid biopsy platform, along with associated reagents, consumables, and CLIA-accredited Precision Biology laboratory services. The company's offerings enable biopharma, academic medical research, and contract research customers to perform 20-channel single-round multiplex tissue imaging and ultra-sensitive circulating tumor cell analysis for biomarker development and clinical trial testing.

Is RareCyte a public or private company?

RareCyte is a private company. It is classified as venture growth investor backed and is currently operating.

When was RareCyte founded?

RareCyte was founded in 2006. It employs 51 to 100 people.

Where is RareCyte based?

RareCyte is headquartered in Seattle, United States, in the North America region.

How does RareCyte make money?

Four revenue lines are on record. Spatial Biology Instruments are the primary driver. The others are reagents and Consumables, precision Biology Services and software Applications.

Who are RareCyte's main competitors?

Direct peers on record are 10x Genomics, NanoString Technologies (Bruker Spatial Biology), Akoya Biosciences and Menarini Silicon Biosystems. Emerging players are Stellaromics and Curio Bioscience. Broad incumbents are Standard BioTools (formerly Fluidigm), Bruker Corporation and Bio-Techne. NeoGenomics is listed as an others.

Does RareCyte have an API?

No public API is recorded for RareCyte.

What industry is RareCyte in?

RareCyte's product category is Life Sciences Research Instruments. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 621511 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogRareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership AppointmentRareCyte launched Orion HT and LE spatial proteomics systems and appointed Neil Kennedy as president. The Orion platform extends from assay development through clinical trials, with a reagent portfolio of over 200 validated antibodies, expected to reach 300 by 2026.FierceBiotechSpatial Biomarker Panels for Clinical TrialsA webinar discusses the advances in multiplex immunofluorescence (mIF) technology that enable high-plex biomarker panels for clinical trials, addressing previous barriers related to validation, customization, and throughput. The session highlights how RareCyte's Orion platform and collaborations with CRO experts facilitate high-dimensional tissue analysis in immuno-oncology research.GlobeNewswireSpatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding MomentumThe global spatial biology market is projected to grow from $1.89 billion in 2025 to $6.39 billion by 2035, a 13.1% CAGR. Key players include 10x Genomics, Bruker, and Akoya, with startups Stellaromics and RareCyte receiving venture funding. The report highlights AI integration and antibody-independent technologies as future opportunities.YahooSpatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding MomentumThe global spatial biology market is projected to reach $6.39 billion by 2035, driven by spatial transcriptomics and multi-omics integration. Key players include 10x Genomics, Bruker, and Akoya, with startups Stellaromics and RareCyte receiving significant venture funding. AI integration and technological advancements are expected to further expand adoption.YahooSpatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding MomentumResearchAndMarkets.com has published a market analysis report projecting the global spatial biology market to reach $6.39 billion by 2035, driven by advancements in precision medicine and drug development. Key industry players including Bruker Corporation, 10x Genomics, Akoya Biosciences, Stellaromics, and RareCyte are actively shaping the competitive landscape through strategic acquisitions, partnerships, and significant venture funding.PR NewswireRareCyte® Announces Research Grant to Investigate Molecular Profile of Circulating Trophoblasts in Fetal Growth RestrictionRareCyte received a $500K Gates Foundation grant to study circulating trophoblasts in fetal growth restriction. The two-phase study will profile 30 pregnant women at Groote Schuur Hospital in South Africa using RareCyte's TrophoSeq assay. Results are expected in the first half of 2026.DiagnosticsworldnewsAI Taking on the Holy Grail of Diagnostics: Predicting Drug ResponseHarvard Medical School professor Peter Sorger argues that machine learning models can outperform radiologists in processing complex tissue images to predict drug response, yet most cancer patients receive drugs without knowing whether they will respond. He cites IQVIA data showing biomarker investment is roughly 100 times smaller than new medicine development, and notes about 6% of diagnoses are impacted by genetic markers. Sorger's team, partnering with RareCyte, has sold about 50 Orion imaging platforms.Pulse 2.0RareCyte: $20 Million Raised To Expand Orion Spatial Biology PlatformRareCyte raised $20 million from new and existing investors, including Forest Road, to expand its Orion Spatial Biology platform. The funding will support new multiplex assays, reagents, software, and global commercial expansion outside the US.FinSMEsRareCyte Secures $20M FinancingRareCyte, a Seattle-based precision biology company, raised $20M in funding led by Forest Road, Arboretum Ventures, and F-Prime Capital. The company will use the funds to expand its Orion spatial biology platform, commercialize new assays, and support its Precision Biology Services. The funding is expected to support expansion of its services, including spatial biology and liquid biopsy assays.VC News DailyRareCyte Raises $20M Financing RoundRareCyte, a Life Sciences company providing Precision Biology platforms, announced the completion of a $20 million financing round from new and existing investors. The funding will support expansion of the Orion Spatial Biology platform including new multiplex assays, reagent products, and software applications, as well as growth of Precision Biology Services including spatial biology and liquid biopsy assays from their Seattle-based CLIA and ISO 13485 certified labs. New investor Forest Road joined existing investors including co-leaders Arboretum Ventures and F-Prime Capital, along with HealthQuest Capital, 5AM Ventures, Agilent Technologies, Sheatree Capital, and GKCC LLC.